ANAB – AnaptysBio Inc
ANAB — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
18.02
Margin Of Safety %
-20
Put/Call OI Ratio
0.98
EPS Next Q Diff
2.22
EPS Last/This Y
0.23
EPS This/Next Y
5.47
Price
56.62
Target Price
81.5
Analyst Recom
1.12
Performance Q
-15.46
Upside
-166.8%
Beta
0.86
Ticker: ANAB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ANAB | 69.66 | 1.11 | 0.04 | 2146 |
| 2026-07-14 | ANAB | 62.35 | 1.01 | 2.69 | 2248 |
| 2026-07-15 | ANAB | 55.88 | 1.06 | 2.56 | 2374 |
| 2026-07-16 | ANAB | 54.09 | 1.30 | 6.14 | 2990 |
| 2026-07-17 | ANAB | 57.96 | 1.25 | 0.10 | 2933 |
| 2026-07-20 | ANAB | 50.27 | 1.28 | 0.98 | 1905 |
| 2026-07-21 | ANAB | 53.75 | 1.05 | 1.12 | 7972 |
| 2026-07-22 | ANAB | 52.52 | 1.06 | 2.83 | 8345 |
| 2026-07-23 | ANAB | 54.96 | 1.06 | 3.47 | 8356 |
| 2026-07-24 | ANAB | 54.12 | 1.03 | 0.03 | 8354 |
| 2026-07-27 | ANAB | 53.63 | 1.01 | 6.91 | 8438 |
| 2026-07-28 | ANAB | 52.07 | 1.02 | 0.36 | 8477 |
| 2026-07-29 | ANAB | 52.11 | 1.02 | 0.71 | 8470 |
| 2026-07-30 | ANAB | 54.98 | 1.01 | 0.00 | 8576 |
| 2026-07-31 | ANAB | 53.39 | 0.99 | 0.67 | 8644 |
| 2026-08-03 | ANAB | 53.62 | 0.99 | 4.67 | 8649 |
| 2026-08-04 | ANAB | 55.17 | 0.99 | 4.67 | 8649 |
| 2026-08-05 | ANAB | 54.89 | 0.99 | 2.33 | 8652 |
| 2026-08-07 | ANAB | 56.65 | 0.98 | 0.00 | 8696 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ANAB | 69.71 | 110.6 | -59.2 | -0.23 |
| 2026-07-14 | ANAB | 62.44 | 110.6 | -58.7 | -0.23 |
| 2026-07-15 | ANAB | 55.82 | 110.6 | -58.7 | -0.23 |
| 2026-07-16 | ANAB | 54.13 | 110.6 | -59.0 | -0.23 |
| 2026-07-17 | ANAB | 58.04 | 110.6 | -59.3 | -0.23 |
| 2026-07-20 | ANAB | 50.29 | 110.6 | -58.6 | -0.23 |
| 2026-07-21 | ANAB | 53.76 | 110.6 | -59.3 | -0.23 |
| 2026-07-22 | ANAB | 52.67 | 110.6 | -59.0 | -0.23 |
| 2026-07-23 | ANAB | 54.97 | 110.6 | -59.2 | -0.23 |
| 2026-07-24 | ANAB | 54.12 | 110.6 | -59.0 | -0.23 |
| 2026-07-27 | ANAB | 53.65 | 110.6 | -59.0 | -0.23 |
| 2026-07-28 | ANAB | 52.04 | 110.6 | -58.9 | -0.23 |
| 2026-07-29 | ANAB | 52.16 | 110.6 | -59.1 | -0.23 |
| 2026-07-30 | ANAB | 54.96 | 110.6 | -59.3 | -0.23 |
| 2026-07-31 | ANAB | 53.28 | 110.6 | -58.9 | -0.23 |
| 2026-08-03 | ANAB | 53.69 | 110.6 | -59.1 | -0.23 |
| 2026-08-04 | ANAB | 53.69 | 110.6 | -59.1 | -0.23 |
| 2026-08-05 | ANAB | 54.97 | 110.6 | -59.1 | -0.23 |
| 2026-08-06 | ANAB | 54.79 | 110.6 | -59.0 | -0.23 |
| 2026-08-07 | ANAB | 56.62 | 110.6 | -59.2 | -0.23 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ANAB | -3.10 | 2.34 | 18.55 |
| 2026-07-14 | ANAB | -3.10 | 2.34 | 18.55 |
| 2026-07-15 | ANAB | -3.10 | 2.34 | 18.55 |
| 2026-07-16 | ANAB | -3.10 | 2.34 | 18.55 |
| 2026-07-17 | ANAB | -2.54 | 2.34 | 18.55 |
| 2026-07-20 | ANAB | -2.54 | 2.44 | 18.55 |
| 2026-07-21 | ANAB | -2.54 | 2.44 | 18.55 |
| 2026-07-22 | ANAB | -2.54 | 2.44 | 18.55 |
| 2026-07-23 | ANAB | -2.54 | 2.44 | 18.55 |
| 2026-07-24 | ANAB | -2.54 | 2.44 | 18.55 |
| 2026-07-27 | ANAB | -2.54 | 0.29 | 18.02 |
| 2026-07-28 | ANAB | -2.54 | 0.29 | 18.02 |
| 2026-07-29 | ANAB | -2.54 | 0.29 | 18.02 |
| 2026-07-30 | ANAB | -2.54 | 0.29 | 18.02 |
| 2026-07-31 | ANAB | -2.54 | 0.29 | 18.02 |
| 2026-08-03 | ANAB | -2.54 | 0.61 | 18.02 |
| 2026-08-04 | ANAB | -2.54 | 0.61 | 18.02 |
| 2026-08-05 | ANAB | -2.54 | 0.61 | 18.02 |
| 2026-08-06 | ANAB | -2.54 | 0.61 | 18.02 |
| 2026-08-07 | ANAB | -2.54 | 0.61 | 18.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.84
Avg. EPS Est. Current Quarter
0.14
Avg. EPS Est. Next Quarter
0.38
Insider Transactions
-2.54
Institutional Transactions
0.61
Beta
0.86
Average Sales Estimate Current Quarter
20
Average Sales Estimate Next Quarter
22
Fair Value
45.11
Quality Score
66
Growth Score
53
Sentiment Score
86
Actual DrawDown %
21.8
Max Drawdown 5-Year %
-69.3
Target Price
81.5
P/E
Forward P/E
28.95
PEG
P/S
7.21
P/B
128.93
P/Free Cash Flow
380.08
EPS
-1.08
Average EPS Est. Cur. Y
-0.23
EPS Next Y. (Est.)
5.24
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-11.53
Relative Volume
0.82
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-59.2
◆
ANAB
Healthcare
$56.61
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
50.6
Range 1M
30.9%
Sup Dist
5.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-393.4%
EPS NY
229.3%
52W%
73.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+114.7% upside
Upside
+114.7%
Quality
66
MoS
-20%
ANAB — P/E HistoricalBiotechnology
AnaptysBio, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 104
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB
Latest News
—
Caricamento notizie per ANAB…
stock quote shares ANAB – AnaptysBio Inc Stock Price stock today
news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANAB – AnaptysBio Inc yahoo finance google finance
stock history ANAB – AnaptysBio Inc invest stock market
stock prices ANAB premarket after hours
ticker ANAB fair value insiders trading